Abstract

BackgroundFamily screening for hypertrophic cardiomyopathy (HCM) is based on genetic testing and clinical evaluation (maximal left ventricular wall thickness (MWT) ≥15 mm, or ≥13 mm in first-degree relatives of HCM patients). The aim of this study was to assess the effect of gender and body size on diagnosis of HCM and prediction of clinical outcome.MethodsThis study includes 199 genotype-positive subjects (age 44 ± 15 years, 50% men) referred for cardiac screening. Gender-specific reference values for MWT indexed by body surface area (BSA), height and weight were derived from 147 healthy controls. Predictive accuracy of each method for HCM-related events was assessed by comparing areas under the receiver operating characteristic curves (AUC).ResultsMen had a higher absolute, but similar BSA- and weight-indexed MWT compared with women (14.0 ± 3.9 mm vs 11.5 ± 3.8 mm, p < 0.05; 6.8 ± 2.1 mm/m2 vs 6.6 ± 2.4 mm/m2; 0.17 ± 0.06 mm/kg vs 0.17 ± 0.06 mm/kg, both p > 0.05). Applying BSA- and weight-indexed cut-off values decreased HCM diagnoses in the study group (48% vs 42%; 48% vs 39%, both p < 0.05), reclassified subjects in the largest, lightest and heaviest tertiles (≥2.03 m2: 58% vs 45%; ≤70 kg: 37% vs 46%; ≥85 kg: 53% vs 25%, all p < 0.05) and improved predictive accuracy (AUC 0.76 [95% CI 0.69–0.82] vs 0.78 [0.72–0.85]; and vs 0.80 [0.74–0.87]; both p < 0.05).ConclusionsIn genotype-positive subjects referred for family screening, differences in MWT across gender are mitigated after indexation by BSA or weight. Indexation decreases the prevalence of HCM, particularly in larger men, and improves the predictive accuracy for HCM-related events.

Highlights

  • Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease, with a prevalence of 0.2–0.5% in the general population [1]

  • In genotype-positive subjects referred for family screening, differences in MWT across gender are mitigated after indexation by body surface area (BSA) or weight

  • Correcting for body size decreases the number of hypertrophic cardiomyopathy (HCM) diagnoses, in larger men

Read more

Summary

Methods

This study included 199 first-degree genotype-positive relatives of HCM patients (99 men, mean age 44 years, range 17–82 years) referred for cardiac screening between 1995 and 2018. A cut-off value was derived from the mean MWT/BSA plus two standard deviations. This was repeated for height and weight separately. As the diagnosis of HCM lacks a true gold standard, HCM-related endpoints were considered surrogate markers of disease presence, allowing comparison of the diagnostic accuracy of the different methods These included HCM-related mortality, cardiac transplantation, implantable cardioverter-defibrillator (ICD) implantation and septal reduction therapy. Data are expressed as mean ± standard deviation BSA body surface area; MWT maximal wall thickness.

Introduction
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call